Givosiran + 5-probe cocktail
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Intermittent Porphyria (AIP)
Conditions
Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent, Acute Porphyria
Trial Timeline
Apr 26, 2018 → Jan 10, 2019
NCT ID
NCT03505853About Givosiran + 5-probe cocktail
Givosiran + 5-probe cocktail is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Acute Intermittent Porphyria (AIP). The current trial status is completed. This product is registered under clinical trial identifier NCT03505853. Target conditions include Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03505853 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Intermittent Porphyria (AIP)